Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Cytokinetics To Contact Him Directly To Discuss Their Options If you suffered losses in Cytokinetics between December 27, 2023 and May 6, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK, Sept. 30, 2025 (GLOBE NEWSWIRE) -- Faruqi & Faruqi ...

NEW YORK, Sept. 29, 2025 (GLOBE NEWSWIRE) -- Wolf Haldenstein Adler Freeman & Herz LLP reminds securities class action lawsuit has been filed in the United States District Court for the Northern District of California on behalf of all individuals and entities who purchased or otherwise acquired Cytokinetics, Incorporated (NASDAQ: CYTK) (“Cytokinetics” or the “Company”) securities between December 27, 2023, and May 6, 2025 (the “Class Period”). PLEASE CLICK HERE TO JOIN THE CASE AND SUBMIT CONTACT INFORMATIO ...

NEW YORK, Sept. 29, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Cytokinetics, Incorporated (NASDAQ: CYTK). Shareholders who purchased shares of CYTK during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/cytokinetics-incorporated-loss-submission-form/?id=169623&from=3 CLASS ...

One important metric to look for in a stock is an 80 or higher Relative Strength Rating. Cytokinetics (CYTK) stock cleared that benchmark Monday, with a jump from 78 to 83 Monday. Â Hone Your Stock-Picking Skills By Focusing On These Factors IBD's proprietary RS Rating identifies market leadership by showing how a stock's price movement over the last 52… Related news Ginkgo Bioworks Holdings Stock Scores RS Rating Upgrade 9/29/2025Ginkgo Bioworks Holdings sees its Relative Strength Rating move into the elit ...

Accessibility StatementSkip Navigation NEW YORK, Sept. 29, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Cytokinetics, Incorporated (NASDAQ: CYTK). Shareholders who purchased shares of CYTK during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/cytokinetics-incorporated-loss-su ...

Core Insights - Aficamten shows significant improvements in exercise capacity and recovery compared to metoprolol in patients with obstructive hypertrophic cardiomyopathy (oHCM) and demonstrates long-term efficacy and tolerability in non-obstructive hypertrophic cardiomyopathy (nHCM) patients [1][2][6] Group 1: MAPLE-HCM Study Findings - Aficamten demonstrated a statistically significant improvement in peak oxygen uptake (pVO2) with a treatment difference of +2.3 mL/kg/min (p<0.001) compared to metoprolol [3] - Additional analyses revealed improvements in submaximal exercise performance, including anaerobic threshold (+76 mL, p<0.001) and aerobic efficiency (+0.8 mL/min/watt, p=0.004) [4][5] - Aficamten also improved post-exercise recovery metrics, with a faster VO2 recovery rate compared to metoprolol [3] Group 2: FOREST-HCM Study Findings - In the FOREST-HCM study, 79% of patients with nHCM improved by at least one NYHA Functional Class after 96 weeks of treatment, with 74% becoming asymptomatic [7] - Aficamten led to a mean increase of 11.2 points in the Kansas City Cardiomyopathy Questionnaire Clinical Summary Score (KCCQ-CSS) [7] - Cardiac biomarkers such as NT-proBNP and high-sensitivity cardiac troponin I showed significant declines by Week 12 and remained low through Week 96 [7] Group 3: Aficamten Overview - Aficamten is a selective cardiac myosin inhibitor designed to reduce myocardial hypercontractility associated with hypertrophic cardiomyopathy (HCM) [9] - The drug is currently under evaluation in multiple clinical trials, including ACACIA-HCM for nHCM and CEDAR-HCM for pediatric patients with oHCM [11] - Aficamten has received Breakthrough Therapy Designation from the FDA for symptomatic HCM and is undergoing regulatory review in the U.S., Europe, and China [13]

Core Viewpoint - A class action lawsuit has been filed against Cytokinetics, alleging securities fraud and unlawful business practices related to the company's New Drug Application for aficamten [1]. Summary by Relevant Sections Class Action Details - Investors are encouraged to contact Pomerantz LLP to join the class action, with a deadline to appoint a Lead Plaintiff by November 17, 2025 [1]. - The lawsuit centers on whether Cytokinetics and its officers engaged in fraudulent activities concerning their securities [1]. FDA Interaction and Stock Impact - On March 10, 2025, Cytokinetics announced that the FDA would not hold an advisory committee meeting for aficamten's NDA [1]. - The FDA extended the action date for aficamten's NDA from September 26, 2025, to December 26, 2025, due to the need for a Risk Evaluation and Mitigation Strategy (REMS) that was not included in the original NDA [1]. - Following this announcement, Cytokinetics' stock price dropped by $5.57, or 12.98%, closing at $37.35 on May 2, 2025 [1]. - On May 6, 2025, CEO Robert I. Blum revealed that the company had multiple pre-NDA meetings with the FDA but chose to submit the NDA without a REMS, leading to a further stock price decline of $2.70, or 7.36%, closing at $33.97 [1].

Core Viewpoint - A class action lawsuit has been filed against Cytokinetics, Inc. for allegedly making false and misleading statements regarding the New Drug Application (NDA) for aficamten, which may have caused investor losses during the specified Class Period from December 27, 2023, to May 6, 2025 [1][5]. Group 1: Lawsuit Details - The lawsuit claims that Cytokinetics misrepresented the expected timeline for FDA approval of aficamten, indicating it would occur in the second half of 2025, while failing to disclose risks related to the submission of a Risk Evaluation and Mitigation Strategy (REMS) [5]. - Investors who purchased Cytokinetics common stock during the Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. Group 2: Legal Representation - The Rosen Law Firm, which has a strong track record in securities class actions, is representing the investors and encourages them to select qualified counsel with proven success [4]. - The firm has recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone, and has been recognized for its leadership in securities class action settlements [4]. Group 3: Next Steps for Investors - Investors wishing to join the class action can do so by visiting the provided link or contacting the firm directly for more information [3][6]. - A lead plaintiff must be appointed by November 17, 2025, to represent the interests of the class members in the litigation [1][3].

LOS ANGELES, Sept. 26, 2025 (GLOBE NEWSWIRE) -- The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies.  Investors have until the deadlines listed below to file a lead plaintiff motion. Investors suffering losses on their investments are encouraged to contact The Law Offices of Frank R. Cruz to discuss their legal rights in these class actions at 310-914-5007 or by email to fcruz@frankcruzlaw.com. Cyt ...

NEW YORK, Sept. 25, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of common stock of Cytokinetics, Inc. (NASDAQ: CYTK) between December 27, 2023 and May 6, 2025, both dates inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than November 17, 2025. SO WHAT: If you purchased Cytokinetics common stock duri ...